solutions. We analysed all in-patients who were fed with PN in presence of central venous catheter and aged 1-18 years. We excluded patients with kidney or liver failures and children with severe congenital or metabolic abnormalities.
The standard formula used in this study was chosen among the formulas present on the market at that time and indicated for adult patients because it was the most suitable in our opinion to meet children's nutritional needs. Particularly we used Oliclinomel N4-550 by Baxter S.p.A. (Rome, Italy). To choose the solution we compared the composition of each parenteral formula with the paediatric needs according to the ESPEN guidelines. 1 The same commercial standard formula (added with calcium reaching the concentration of 4 mmol/l) was administered to multiple patients in different volumes calculated in relation to body weight.
The group PED STD-PN received five different standardised formulations according to their age. Total volume administered ranged from 1100 to 2200 ml/day, with amino acids, glucose and lipids intakes between 1.84-1.28, 9.22-3.34 and 2.58-1.15 g/Kg/day, respectively. Micronutrients were administered according to ESPEN guidelines. 1 PN tolerance was checked analysing plasma biochemical parameters: glucose, triglycerides, sodium, potassium, calcium, magnesium and phosphate 1, 10 before starting treatment (basal values), at 3 and 7 days of treatment and, afterward, once a week throughout PN administration. If a patient was out of range for any of the above mentioned parameters and needed a personalised formula he was dropped out of the study.
The groups' baseline comparability was conducted with Kruskall-Wallis test followed by Dunn test. The time course of biochemical parameters were compared with a non-parametric Table 1 . Mean and s.d. at baseline, 3rd and 7th day of the considered biochemical parameters for the three groups of patients Patients needed PN for an average period of 18.2 ± 11.2, 22.5 ± 21.1 and 18.6 ± 14.5 days in the groups COM STD-PN, PED STD-PN and IND-PN, respectively (P ¼ 0.9427).
Average duration of standard treatment (without the necessity of switching to personalised prescription) was 8 ± 5.87 days for COM STD-PN treatment, whereas that one with PED STD-PN was 12.5±14.2 days (P ¼ 0.2700).
Basal biochemistry was not different at baseline. The biochemical plasma values collected at basal and in the 3rd and 7th days were not statistically different among the three groups (Table 1) .
Our work represents one of the first studies carried out in Italy in order to verify the possibility of using standard commercial or galenic PN formulas in children. The current trend is to have standard solutions available as it is for adult patients also for paediatric ones. The results of this investigation suggest that with adequate monitoring of patient, it is possible to use standard commercial PN formulas for paediatric patients, also if the use of this kind of admixture is restricted to a limited period of time (8-12 days). There were no differences between the duration of the treatment with the commercial formula and the galenic standard formula. Standard commercial formulas can be used as starter admixtures, allowing paediatricians to have more time to evaluate the clinical conditions of patients and to formulate the most appropriate personalised solution when it is necessary. Furthermore 8 days could be a time still sufficient to cover the requirements in case of emergency. Owing to the numerous advantages of standard solution use, these preparations could be considered as a viable alternative to personalisation at least for the 1st week of treatment, though these data must be confirmed with a larger number of patients. Personalised prescriptions are indicated for paediatric patients with critical condition, metabolically unstable and for long-term PN treatment. This study evaluated the tolerability of PN treatment with standardised commercial formulas; it remains to verify the effectiveness of this nutritional support for a longer period of time. Furthermore, we analysed the tolerability of a single standard commercial formula used for all COM STD-PN patients; just as there are different standard formulas for adult patients to choose according to the clinical conditions, the same will be possible for paediatric patients.
In conclusion standardised paediatric PN was tolerated for 8-12 days. No differences were detected in plasma values of the more common biochemical parameters. Standardised paediatric PN formula could be a safe and useful alternative to compounding at least in the first days of PN requirements.
